AKBA · Akebia Therapeutics, Inc. · Earnings Call Transcripts & Audio
$0.89
-0.03 (-3.76%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$244.05M
Shares
277.11M
Volume · Oct 1
812.55K
Avg daily vol (3M)
6.05M
Akebia Therapeutics, Inc. Earnings Call Transcripts
Quarterly earnings calls for Akebia Therapeutics, Inc. (AKBA), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼0.1%
$48.71M
−$54.10M
'22 Q3
22-11-03
▼3.4%
$55.71M
−$6.07M
'22 Q4
23-03-09
▼35.2%
$40.01M
−$26.88M
'23 Q1
23-05-08
▼55.4%
$56.38M
−$11.17M
'23 Q2
23-08-25
▼13.7%
$42.05M
−$14.49M
'23 Q3
23-11-08
▲0.9%
$56.20M
$612,000
'23 Q4
24-01-08
▼18.5%
$32.61M
−$17.98M
'24 Q1
24-05-09
▼22.6%
$43.65M
−$8.58M
'24 Q2
24-08-08
▼11%
$37.43M
−$20.04M
'24 Q3
24-11-07
▼17.3%
$46.50M
−$22.80M
'24 Q4
25-03-13
▲75.8%
$57.34M
$6.11M
'25 Q1
25-05-08
▲43.1%
$62.47M
$247,000
'25 Q2
25-08-07
▲57%
$58.77M
$540,000
'25 Q3
25-11-10
▲23.9%
$57.62M
−$12.24M
'25 Q4
26-02-26
▼6.6%
$53.54M
−$9.05M
'26 Q1
26-05-07
LATEST
▼21.4%
$49.13M
−$8.91M
'26 Q2
26-08-05
Earnings call
FY26 · Q2
2026-08-05
Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript
Confident tone
Pipeline: Prolisiguat (PROLI) in FSGS
Pipeline: Ibribifus (EBRI) in rare kidney diseases
VOICE trial results
Revenue
$49.13M
▼ 21.4% YoY Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
Akebia Therapeutics, Inc. (AKBA) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Akebia Therapeutics, Inc. (AKBA) Q1 2026 Earnings Call Transcript
Confident tone
Vafcio launch performance
Observed dosing protocol adoption
Perlisiguat / FSGS pipeline
Revenue
$53.54M
▼ 6.6% YoY Diluted EPS
$-0.03
▼ 200% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript
Positive tone
Vafseo Commercial Launch
Rare Kidney Disease Pipeline
Q4 2025 Demand Softness
Revenue
$57.62M*
▲ 23.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Akebia Therapeutics, Inc. (AKBA) Q3 2025 Earnings Call Transcript
Positive tone
Dialysis provider partnerships and access expansion
Operational and adherence challenges
Clinical data and standard of care goal
Revenue
$58.77M
▲ 57% YoY Diluted EPS
$0.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript
Confident tone
Vafseo launch progress
Auryxia legacy franchise and generic risk
DaVita and large dialysis provider access
Revenue
$62.47M
▲ 43.1% YoY Diluted EPS
$0.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript
Confident tone
Dialysis organization onboarding and large-provider pilots
Vafseo (vadadustat) US launch and net product revenues
Refills, persistence, and dose titration
Revenue
$57.34M
▲ 75.8% YoY Diluted EPS
$0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-13
Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript
Confident tone
Vafseo U.S. launch performance
Reimbursement mix (Medicare, Medicare Advantage, commercial)
Dialysis organization access and contracting
Revenue
$46.50M*
▼ 17.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Akebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript
Confident tone
Vafseo launch preparation
Dialysis contracting and access
Prescriber demand and awareness
Revenue
$37.43M
▼ 11% YoY Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Akebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call
Revenue
$43.65M
▼ 22.6% YoY Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Akebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call Transcript
Confident tone
Vafseo launch execution
Auryxia entering the bundle
Clinical data and publications
Revenue
$32.61M
▼ 18.5% YoY Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Akebia Therapeutics, Inc. (AKBA) Q4 2023 Earnings Call
Revenue
$56.20M*
▲ 0.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Akebia Therapeutics, Inc. (AKBA) Q3 2023 Earnings Call Transcript
Revenue
$42.05M
▼ 13.7% YoY Diluted EPS
$-0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-25
Akebia Therapeutics, Inc. (AKBA) Q2 2023 Earnings Call Transcript
Revenue
$56.38M
▼ 55.4% YoY Diluted EPS
$-0.06
▼ 140% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Akebia Therapeutics, Inc. (AKBA) Q1 2023 Earnings Call Transcript
Revenue
$40.01M
▼ 35.2% YoY Diluted EPS
$-0.15
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-09
Akebia Therapeutics, Inc. (AKBA) Q4 2022 Earnings Call Transcript
Revenue
$55.71M*
▼ 3.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Akebia Therapeutics, Inc. (AKBA) Q3 2022 Earnings Call Transcript
Revenue
$48.71M
▼ 0.1% YoY Diluted EPS
$-0.29
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Akebia Therapeutics, Inc. (AKBA) Q2 2022 Earnings Call Transcript
Revenue
$126.36M
▲ 138.8% YoY Diluted EPS
$0.15
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Akebia Therapeutics, Inc. (AKBA) Q1 2022 Earnings Call Transcript
Revenue
$61.70M
▲ 18% YoY Diluted EPS
$-0.35
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q3
2021-11-04
Akebia Therapeutics, Inc. (AKBA) Q3 2021 Earnings Call Transcript
Revenue
$48.76M
▼ 18.7% YoY Diluted EPS
$-0.34
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Akebia Therapeutics, Inc. (AKBA) Q2 2021 Earnings Call Transcript
Revenue
$52.91M
▼ 41.3% YoY Diluted EPS
$-0.51
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Akebia Therapeutics, Inc. (AKBA) Q1 2021 Earnings Call Transcript
Revenue
$52.30M
▼ 40.9% YoY Diluted EPS
$-0.45
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Akebia Therapeutics, Inc. (AKBA) Q4 2020 Earnings Call Transcript
Revenue
$56.04M*
▼ 19.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Akebia Therapeutics, Inc. (AKBA) Q3 2020 Earnings Call Transcript
Revenue
$59.99M
▼ 34.8% YoY Diluted EPS
$-0.42
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Akebia Therapeutics, Inc. (AKBA) Q2 2020 Earnings Call
Revenue
$90.14M
▼ 10.6% YoY Diluted EPS
$-1.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Akebia Therapeutics, Inc. (AKBA) Q1 2020 Earnings Call Transcript
Revenue
$88.48M
▲ 21.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-10
Akebia Therapeutics, Inc. (AKBA) Q4 2019 Earnings Call
Revenue
$69.56M*
▲ 16.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 earnings calls